Top

Strahlentherapie und Onkologie

Published in:

01-02-2013 | Original article

Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors

Authors: Prof. Dr. M. Kocher, H. Treuer, M. Hoevels, R. Semrau, V. Sturm, R.-P. Mueller

Published in: Strahlentherapie und Onkologie | Issue 2/2013

Abstract

Purpose

To find out whether the use of stereotactic techniques for fractionated radiotherapy reduces toxicity to the endocrine and visual system in patients with benign perioptic tumors.

Patients and methods

From 1993 to 2009, 29 patients were treated with fractionated stereotactic radiotherapy. The most frequent tumor types were grade I meningioma (n = 11) and pituitary adenoma (n = 10, 7 nonfunctioning, 3 growth hormone-producing). Patients were immobilized with the GTC frame (Radionics, USA) and the planning target volume (PTV; median 24.7, 4.6–58.6 ml) was irradiated with a total dose of 52.2 Gy (range, 45.0–55.8 Gy) in 1.8-Gy fractions using a linear accelerator (6 MeV photons) equipped with a micro-multileaf collimator. Maximum doses to the optic system and pituitary gland were 53.4 Gy (range, 11.5–57.6 Gy) and 53.6 Gy (range, 12.0–57.9 Gy).

Results

Median follow-up was 45 months (range, 10–105 months). Local control was achieved in all but 1 patient (actuarial rate 92% at 5 years and 10 years). In 9 of 29 patients (31%), partial remission was observed (actuarial response rate 40% at 5 years and 10 years). In 4 of 26 patients (15%) with at least partial pituitary function, new hormonal deficits developed (actuarial rate 21% at 5 years and 10 years). This rate was significantly higher in patients treated for a larger PTV (< /> 25 ml: 0% vs. 42% at 5 years and 10 years, p = 0.028). Visual function improved in 4 of 15 patients (27%) who had prior impairment. None of the patients developed treatment-related optic neuropathy, but 2 patients experienced new disease-related visual deficits.

Conclusion

Fractionated stereotactic radiotherapy for benign tumors of the perioptic and sellar region results in satisfactory response and local control rates and does not affect the visual system. The assumption that patients can be spared hypophyseal insufficiency only holds for small tumors.

Voges J, Kocher M, Runge M et al (2006) Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer 107:1355–1364PubMedCrossRef

Ruge MI, Kocher M, Maarouf M et al (2011) Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther Onkol 187:7–14PubMedCrossRef

Runge M, Maarouf M, Hunsche S et al (2012) Linac radiosurgery for nonsecreting pituitary adenomas: long-term results. Strahlenther Onkol 188:319–327PubMedCrossRef

Becker G, Kocher M, Kortmann R et al (2002) Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol 178:173–186PubMedCrossRef

Minniti G, Amichetti M, Enrici RM (2009) Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncology 4:42CrossRef

Minniti G, Scaringi C, Enrici RM (2011) Radiation techniques for acromegaly. Radiat Oncology 6:167CrossRef

D’Agostino GR, Autorino R, Pompucci A et al (2011) Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis. Strahlenther Onkol 187:421–425CrossRef

Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol 186:558–564PubMedCrossRef

Zwicker F, Hauswald H, Nill S et al (2010) New multileaf collimator with a leaf width of 5 mm improves plan quality compared to 10 mm in step-and-shoot IMRT of HNC using integrated boost procedure. Strahlenther Onkol 186:334–343PubMedCrossRef

10.

Milker-Zabel S, Huber P, Schlegel W et al (2009) Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas. J Neurooncol 94:419–424PubMedCrossRef

11.

Minniti G, Traish D, Ashley S et al (2006) Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin Endocrinol 64:542–548CrossRef

12.

Saeed P, Blank L, Selva D et al (2010) Primary radiotherapy in progressive optic nerve sheath meningiomas: a long term follow-up study. Br J Ophthalmol 94:564–568PubMedCrossRef

13.

Baumert BG, Villa S, Studer G et al (2004) Early improvements in vision after fractionated stereotactic radiotherapy for primary optic nerve sheath meningioma. Radiother Oncol 72:169–174PubMedCrossRef

14.

Landert M, Baumert BG, Bosch M et al (2005) The visual impact of fractionated stereotactic conformal radiotherapy on seven eyes with optic nerve sheath meningeomas. J neuro-Ophthalmol 25:86–91

15.

Stiebel-Kalish H, Reich E, Gal L et al (2012) Visual outcome in meningiomas around anterior visual pathways treated with linear accelerator fractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 82:779–788PubMedCrossRef

16.

Paulsen F, Doerr S, Wilhelm H et al (2012) Fractionated stereotactic radiotherapy in patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 82:773–778PubMedCrossRef

17.

Adeberg S, Welzel T, Rieken S et al (2011) Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM). Radiat Oncology 6:117CrossRef

18.

Arvold ND, Lessell S, Bussiere M et al (2009) Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 75:1166–1172PubMedCrossRef

19.

Jeremic B, Pitz S (2007) Primary optic nerve sheath meningeoma. Cancer 110:714–722PubMedCrossRef

20.

Combs SE, Schulz-Ertner D, Moschos D et al (2005) Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys 62:814–819PubMedCrossRef

21.

Kanesaka N, Mikami R, Nakayama H et al (2012) Preliminary results of fractionated stereotactic radiotherapy after cyst drainage for craniopharyngioma in adults. Int J Radiat Oncol Biol Phys 82:1356–1360PubMedCrossRef

22.

Combs SE, Thilmann C, Huber PE et al (2007) Achievement of long-term local control in patients with craniopharyngeomas using high precision stereotactic radiotherapy. Cancer 109:2308–2314PubMedCrossRef

23.

Lo SS, Fakiris AJ, Henderson MA et al (2008) Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy in pediatric brain tumors. Expert Rev Neurotherapeutics 8:121–132CrossRef

24.

Minniti G, Saran F, Traish D et al (2007) Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol 82:90–95PubMedCrossRef

25.

Minniti G, Esposito V, Amichetti M, Maurizi Enrici R (2009) The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngeoma. Neurosurg Rev 32:125–132PubMedCrossRef

26.

Elhateer H, Muanza T, Roberge D et al (2008) Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas. Curr Oncol 15:286–292PubMed

27.

Roug S, Rasmussen AK, Juhler M et al (2010) Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. Europ J Endocrinol 162:685–694CrossRef

28.

Colin P, Jovenin N, Delemer B et al (2005) Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys 62:333–341PubMedCrossRef

29.

Schalin-Jaentti C, Valannet L, Tenhunen M et al (2010) Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study. Clin Endocrinol 73:72–77

30.

Paek SH, Downes MB, Bednarz G et al (2005) Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys 61:795–808PubMedCrossRef

31.

Minniti G, Clarke E, Cavallo L et al (2011) Fractionated stereotactic conformal radiotherapy for large benign skull base meningeomas. Radiat Oncology 6:36CrossRef

32.

Onodera S, Aoyama H, Katoh N et al (2011) Long-term outcome of fractionated stereotactic radiotherapy for intracranial skull base meningiomas in single institution. Jpn J Clin Oncol 41:462–468PubMedCrossRef

33.

Behbehani RS, McElveen T, Sergott RC et al (2005) Fractionated stereotactic radiotherapy for parasellar meningeomas: a preliminary report of visual outcomes. Br J Ophthalmol 89:130–133PubMedCrossRef

34.

Milker-Zabel S, Zabel-du Bois A, Huber P et al (2006) Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas. Strahlenther Onkol 182:635–640PubMedCrossRef

35.

Selch M, Ahn E, Laskari A et al (2004) Stereotactic radiotherapy for treatment of cavernous sinus meningeomas. Int J Radiat Oncol Biol Phys 59:101–111PubMedCrossRef

36.

Brell M, Villa S, Teixidor P et al (2006) Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance. Surg Neurol 65:28–34PubMedCrossRef

37.

Litre CF, Colin P, Noudel R et al (2009) Fractionated stereotactic radiotherapy treatment of cavernous sinus meningeomas: a study of 100 cases. Int J Radiat Oncol Biol Phys 74:1012–1017PubMedCrossRef

38.

Trippa F, Maranzano E, Costantini S, Giorgi C (2009) Hypofractionated stereotactic radiotherapy for intracranial meningiomas: preliminary results of a feasibility trial. J Neurosurg 53:7–11

39.

Astner ST, Theodorou M, Dobrei-Ciuchendea M et al (2010) Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after strereotactic radiotherapy of meningiomas. Strahlenther Onkol 186:423–429PubMedCrossRef

40.

Adler J, Gibbs I, Puataweepong P, Chang S (2006) Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurg 59:244–254CrossRef

41.

Bria C, Wegner RE, Clump DA et al (2011) Fractionated stereotactic radiosurgery for the treatment of meningeomas. J Cancer Res Ther 7:52–57PubMedCrossRef

42.

Iwata H, Sato K, Tatewaki K et al (2011) Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro Oncol 13

43.

Kajiwara K, Saito K, Yoshikawa K et al (2005) Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas. Minim Invasive Neurosurg 48:91–96PubMedCrossRef

44.

Killory B, Kresl J, Wait S et al (2009) Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurg 64:A19–A25CrossRef

Title: Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors
Authors: Prof. Dr. M. Kocher
H. Treuer
M. Hoevels
R. Semrau
V. Sturm
R.-P. Mueller
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Strahlentherapie und Onkologie / Issue 2/2013
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0269-y

At a glance: The STEP trials

Springer Medicine

Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors

Abstract

Purpose

Patients and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2013

Lokale Kontrolle bei T3-Rektumkarzinomen

Diffusion-weighted MRI in locally advanced rectal cancer

Intraoperative EBRT and resection for renal cell carcinoma

Resektion plus adjuvante Chemotherapie verbessert Überleben beim fortgeschrittenen Pankreaskarzinom

Karzinom des Ösophagus und des gastroösophagealen Übergangs

Radiotherapy for achillodynia